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background:  Randomized controlled trials (RCT) evaluating thrombus aspiration (TA) before primary percutaneous coronary intervention 
(PCI) vs primary PCI alone have shown a heterogeneous effect on 30 day mortality. We hypothesized that the use of GpIIb/IIIa inhibitors 
along with TA is associated with reduced distal embolization during primary PCI leading to improved 30-day mortality.
methods:  We performed comprehensive search for RCTs comparing concomitant TA with primary PCI vs primary PCI alone that reported 
30-day mortality.
results:  Metaregression of 13 RCTs showed that studies with higher GpIIb/IIIa inhibitor use had higher mortality benefit with TA, 
compared with studies with lower GpIIb/IIIa inhibitor use (0.07 reduction in log-relative risk per 10% increase in GpIIb/IIIa inhibitor use, 
p=0.047, Figure). A second metaregression to evaluate the association between the prevalence of GpIIb/IIIa inhibitors use in the TA arm 
minus the prevalence of GpIIb/IIIa inhibitors use in control arm and all-cause mortality with use of TA showed that studies with higher 
proportion of GpIIb/IIIa inhibitors use in TA arm (than control arm in the same study) showed a higher mortality benefit with TA (0.09 
reduction in log-relative risk for every percent higher GpIIb/IIIa inhibitors use in the TA arm, compared with the control arm, p=0.02).
Conclusion:  Concomitant use of GpIIb/IIIa inhibitors appears to have a synergistic effect with TA on 30 day mortality and may explain 
some of the heterogeneity among the RCTs.
 
